The study aimed to assess the level of ANG‑2 in MM patients at diagnosis and in remission state and elaborate on its correlation with interleukin‑6 (IL‑6) and beta‑2 microglobulin (B2M) levels. Sixty MM patients; 20 newly diagnosed (ND), and 40 patients in remission were included. Twenty healthy individuals were included as a control group. Plasma levels of ANG‑2, B2M, and IL‑6 were tested by enzyme‑lin ked immunosorbent assay. There are significant statistical differences between ND patients and those in remission in hemoglobin, neutrophil count, blood urea, serum creatinine, glomerular filtration rate, B2M, IL6, and ANG‑2 (P = 0.001, 0.033, 0.005, 0.001, 0.001, 0.001, 0.004, and 0.001, respectively). ANG‑2 showed significant positive correlations with B2M (P = 0.001) and IL‑6 (P = 0.012). CONCLUSION: The low ANG‑2 level in the remission group with an insignificant difference from that in the control group with a high level in the untreated patients renders it a useful indicator for treatment response follow‑up in MM. The positive correlation of ANG‑2 with B2M and IL‑6 reflects the active angiogenesis with a high tumor burden and disease progression.
